Strides Arcolab up on USFDA nod for two more anti-cancer drugs

Strides Arcolab gained on Friday after Onco Therapies, a wholly owned subsidiary of the company received two more ANDA approvals.These ANDA approvals are for Fludarabine Phosphate for injection, USP packaged in 50 mg/ 2ml, single use vials, Lyophilized format and Idarubicin Hydrochloride Injection, 1 mg/ ml and 20 ml single-dose vials. Shares ofthe companyare trading at Rs 906, up Rs 9.4, or 1.05% at the Bombay Stock Exchange (BSE) on Friday at 10:16 a.m.The scrip has touched an intra-day high of Rs 908 and low of Rs 894. The total volume of shares traded at the BSE is 11,551.In the earlier session, the shares gained 0.78%, or Rs 6.9, at Rs 896.60. Currently, the stock is trading down 5.44% from its 52-week high of Rs 958.10 and above 150.55% over the 52-week low of Rs 361.60.

Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 887.20 9.40 1.06 1 Month 893.35 3.25 0.36 3 Months 750.60 146.00 19.45 6 Months 657.40 239.20 36.39 1 Year 375.10 521.50 139.03 Note: Based on previous day closing price.